JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

Inclusion Criteria: 1. up to 75 years (Child, Adult) , either sex； 2. Bone marrow cell morphology examination showed the proportion of primitive and immature lymphocytes in the bone marrow is \>5%, or the bone marrow MRD analysis comfirmed as B-ALL. 3. Flow cytometry or histology confirmed positive expression of cluster of differentiation 19 (CD19); 4. According to the researcher's assessment, the expected survival period is greater than 3 months; 5. Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 3; 6. The patient has good liver, kidney, heart, and lung functions: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal(ULN), which can be relaxed to ≤ 5 × ULN for patients with liver invasion; Total serum bilirubin \< 34 μ Mol/L; Creatinine clearance rate\>30 mL/min; Cardiac ejection fraction (EF) ≥ 40%, without pericardial effusion and significant arrhythmia; Indoor oxygen saturation (SpO2) ≥ 92%; 7. Peripheral blood lymphocyte absolute count: absolute lymphocyte count (ALC) ≥ 0.5E9/L, blood platelet (PLT) \> 30E9/L, Hb \> 80g/L, with a single venous access and no other contraindications for blood cell separation; 8. MRI examination showed no active malignant cells in the cerebrospinal fluid, no brain metastases, or no central nervous system leukemia; 9. Individuals with fertility must agree to the use of efficient contraceptive methods; 10. The subject or their legal guardian can understand and voluntarily sign a written informed consent form. Exclusion Criteria: 1. Pregnant or lactating women, as well as women with pregnancy plans within six months; 2. Virological tests of hepatitis B, hepatitis C, AIDS, syphilis and cytomegalovirus were positive; 3. Having a history of other tumors (excluding skin or cervical carcinoma in situ cured by root therapy and without evidence of disease activity); 4. Previously received treatment targeting CD19; 5. Received autologous hematopoietic stem cell transplantation within 6 weeks; 6. The presence of uncontrollable active bacterial or fungal infections; 7. Allergies to research related drugs or cellular components; 8. Active autoimmune diseases exist; 9. Patients with unstable or active ulcers or gastrointestinal bleeding currently present; 10. Individuals with mental or psychological disorders who cannot cooperate with treatment and efficacy evaluation; 11. Received other experimental drug treatments within the past 3 months; 12. Existence of grade II-IV acute graft versus-host disease (GVHD) or widespread chronic GVHD; 13. Researchers believe that other reasons are not suitable for clinical trial participants.